Skip to main content
Evidence Snapshot

Beta-lactamase

CHEMBL5031 SINGLE PROTEIN Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5031
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-lactamase as ChEMBL target CHEMBL5031, mapped to UniProt P24735. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-lactamase
SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
As of 2026-09-13
ChEMBL target ID
CHEMBL5031
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24735
Beta-lactamase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-lactamase matters

As of 2026-09-13

Beta-lactamase is reviewed as Beta-lactamase (UniProt P24735); Beta-lactamase shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 122 compounds, and 95 assays, with lead potency reaching pChEMBL 8.3.

Disease context
infection

Beta-lactamase shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include RELEBACTAM.

Start review with infection because it currently carries approved-linked support. Linked drugs include RELEBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 122 compounds, and 95 assays for this target. The dominant activity type is IC50. CHEMBL1795572 is the current potency anchor at pChEMBL 8.3.

Use CHEMBL1795572 as the tractability anchor when discussing potency (pChEMBL 8.3).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 8.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-lactamase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24735, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why infection is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

122
Total Compounds
95
Total Assays
5
Approved Drugs
IC50: 102.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1795572
 8.3 IC50 —
No preferred name
CHEMBL1795567
 8.1 IC50 —
No preferred name
CHEMBL1795565
 8.0 IC50 —
No preferred name
CHEMBL5409555
 7.8 IC50 —
No preferred name
CHEMBL1795571
 7.7 IC50 —

Approved Drugs

Structure Compound First Approval
AVIBACTAM
CHEMBL1689063
 2015
AVIBACTAM SODIUM
CHEMBL2107817
 2015
TAZOBACTAM
CHEMBL404
 1993
CLAVULANIC ACID
CHEMBL777
 1984
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5031